Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients
Hilvo et al. 2019 Eur Heart J. Published online: 18 June 2019
Read moreZora Biosciences Pushing Ceramide Testing to Assess Cardiovascular Risk
Zora Biosciences is working to expand US and European sales of its ceramide lipid-based cardiovascular risk test, CERT.
Read moreZora Brings Molecular Lipids to the Clinic for Cardiovascular Risk Prediction with Enhanced Capacity
Zora’s laboratory has been able to improve its robotized mass spectrometry workflow such that one machine is able to analyze up to 12 000 samples per…
Read moreSusceptibility of low-density lipoprotein particles to aggregate depends on particle lipidome, is modifiable, and associates with future cardiovascular deaths
Ruuth M. et al. 2018 European Heart Journal, 2018: 39 (27),2562–2573.
Read morePlasma concentrations of molecular lipid species predict long-term clinical outcome in coronary artery disease patients
Anroedh et al. 2018 The Journal of Lipid Research. June 1, 2018, doi: 10.1194/jlr.P081281
Read moreZora participates XXXVI Nordic Congress in Clinical Chemistry -congress in June at Helsinki
Zora participates XXXVI Nordic Congress in Clinical Chemistry in June 12-15, 2018 at Helsinki, Finlandia Hall. Nordic Congress in Clinical Chemistry is notable event in…
Read moreCeramide stearic to palmitic acid ratio predicts incident diabetes
Hilvo et al. Diabetologia (2018) 61: 1424. https://doi.org/10.1007/s00125-018-4590-6
Read morePCSK9 inhibition alters the lipidome of plasma and lipoprotein fractions
Hilvo et al. 2018 Atherosclerosis Volume 269, Pages 159–165
Read moreHigh-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism
Braicu et al. Oncotarget. 2017; 8:102912-102922
Read moreNew Generation Lipid Test: Are Ceramides New Cholesterol?
Scott Summers from University of Utah discusses at Cell Metabolism Journal, could recently introduced ceramide testing become new cholesterol. Zora has developed a ceramide based…
Read morePress Release: Zora Announces CERT – A Validated Test for Cardiovascular and Diabetes Risk Prediction
Espoo, Finland, 3 January 2018 – Zora Biosciences Oy (“Zora”) announces the expansion of its Coronary Event Risk Test (CERT) to include prediction of type…
Read morePlasma ceramides highlighted in European Heart Journal
European Heart Journal recently highlighted Zora's invention, new blood test that predicts cardiovascular events in patients with or without coronary artery disease. The test is…
Read moreZora and ceramides in Science Daily
New blood test developed by Zora Biosciences was featured in Science Daily News on March 10, 2017. The test predicst cardiovascular events in patients with…
Read moreMayo Clinic will present plasma ceramide results at ACC 2017
The CERAM test, released commercially by Mayo Medical Laboratories in August 2016, measures blood concentrations of plasma ceramides, a class of lipids that are highly…
Read moreWhat are plasma ceramides?
Learn what are plasma ceramides and why you should measure your ceramides. Watch Dr. Jeff Meeusen’s informative video on plasma ceramides and their relation to…
Read moreHeart Attack Risk Test, CERT, is available from various medical centers in Finland
Heart Attack Risk Test, CERT, is available from various medical centers in Finland CERT-test measures persons risk of getting a heart attack or even heart-related…
Read moreCirculating Ceramides Predict Cardiovascular Outcomes in the Population-Based FINRISK 2002 Cohort
Havulinna et al. Arterioscler Thromb Vasc Biol. 2016; 36
Read moreCoronary Event Risk Test available in Finland through United Medix Laboratories
Ceramides, Coronary Event Risk Test, CERT Coronary Event Risk Test, CERT, is a new diagnostic test for evaluation of risk of heart attack and CVD-related…
Read moreWe are hiring – Join Zora-team
Zora Biosciences is looking for a Bioinformatician Zora Biosciences Oy is a discovery diagnostics company. Zora identifies, validates and develops novel clinical tools using a…
Read morePlasma Ceramide test is now available at Mayo Clinic Medical Laboratories
Plasma Ceramides predict adverse cardiovascular events. Elevated plasma ceramide concentrations are risk factors for cardiovascular mortality, myocardial infarction and acute coronary syndrome hospitalizations. Plasma ceramides…
Read more